TRENDS IN ICER-BASED HEOR RESEARCH FROM TURKIYE: AN ANALYSIS OF ISPOR ABSTRACTS (2021-2025)
Author(s)
Selin Okcun, MSc1, Mustafa KURNAZ, MSc2, Guvenc Kockaya, MSc, PhD, MD3, OZNUR SEYHUN, BSc, MFE, MSc3.
1Health Economist, Econix Research, İstanbul, Turkey, 2Econix Research, İstanbul, Turkey, 3Econix Research, Tallin, Estonia.
1Health Economist, Econix Research, İstanbul, Turkey, 2Econix Research, İstanbul, Turkey, 3Econix Research, Tallin, Estonia.
OBJECTIVES: This study aims to examine the trend of Türkiye-related HEOR studies focusing on cost-effectiveness analyses presented at ISPOR meetings between 2021-2025.
METHODS: The ISPOR online database was searched using “Turkey”,“Turkiye”,and “Türkiye” as keywords.Abstracts were screened according to release date,title,and content.Studies were included if they were related to Türkiye and reported economic evaluations.Among these, studies identified as cost-effectiveness analyses were further reviewed for reported ICER values.A comprehensive list of cost-effectiveness studies was prepared, including relevant clinical,ICER, and economic values.ICER findings were interpreted using commonly applied willingness-to-pay thresholds based on annual GDP per capita. Türkiye’s GDP per capita values used in the analysis were ₺85,672 for 2021, ₺176,589 for 2022, ₺311,109 for 2023,and ₺503,076 for 2024.
RESULTS: A total of 1,453 studies were identified since 2000 using the search criteria.After excluding studies published before 2021, 398 studies remained.Duplicate records were removed, resulting in 170 distinct post-2021 articles. Following title screening, 144 distinct Türkiye-related studies from 2021-2025 were identified. The annual number of submissions was 6 in 2021, 41 in 2022, 37 in 2023, 26 in 2024, and 33 in 2025. Abstract screening showed that only 13 studies were full cost-effectiveness analyses. Reported ICER values were interpreted according to GDP per capita thresholds: below GDP per capita, between 1-3 times GDP per capita, and above 3 times GDP per capita. Among 16 treatment options analyzed, 6 had ICER values below annual GDP per capita, 6 were between 1-3 times GDP per capita, and 4 were dominant compared with baseline treatment.
CONCLUSIONS: Cost-effectiveness studies represent a limited but meaningful share of Türkiye-related HEOR presentations at ISPOR.Interpreting ICER values using GDP per capita thresholds provides practical insight for reimbursement and market access decision-making.Overall, findings suggest that cost-effectiveness analyses are valuable not only for their numerical ICER results but also for their implications for economic feasibility and healthcare decision-making.
METHODS: The ISPOR online database was searched using “Turkey”,“Turkiye”,and “Türkiye” as keywords.Abstracts were screened according to release date,title,and content.Studies were included if they were related to Türkiye and reported economic evaluations.Among these, studies identified as cost-effectiveness analyses were further reviewed for reported ICER values.A comprehensive list of cost-effectiveness studies was prepared, including relevant clinical,ICER, and economic values.ICER findings were interpreted using commonly applied willingness-to-pay thresholds based on annual GDP per capita. Türkiye’s GDP per capita values used in the analysis were ₺85,672 for 2021, ₺176,589 for 2022, ₺311,109 for 2023,and ₺503,076 for 2024.
RESULTS: A total of 1,453 studies were identified since 2000 using the search criteria.After excluding studies published before 2021, 398 studies remained.Duplicate records were removed, resulting in 170 distinct post-2021 articles. Following title screening, 144 distinct Türkiye-related studies from 2021-2025 were identified. The annual number of submissions was 6 in 2021, 41 in 2022, 37 in 2023, 26 in 2024, and 33 in 2025. Abstract screening showed that only 13 studies were full cost-effectiveness analyses. Reported ICER values were interpreted according to GDP per capita thresholds: below GDP per capita, between 1-3 times GDP per capita, and above 3 times GDP per capita. Among 16 treatment options analyzed, 6 had ICER values below annual GDP per capita, 6 were between 1-3 times GDP per capita, and 4 were dominant compared with baseline treatment.
CONCLUSIONS: Cost-effectiveness studies represent a limited but meaningful share of Türkiye-related HEOR presentations at ISPOR.Interpreting ICER values using GDP per capita thresholds provides practical insight for reimbursement and market access decision-making.Overall, findings suggest that cost-effectiveness analyses are valuable not only for their numerical ICER results but also for their implications for economic feasibility and healthcare decision-making.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD77
Topic
Real World Data & Information Systems
Topic Subcategory
Data Protection, Integrity, & Quality Assurance
Disease
No Additional Disease & Conditions/Specialized Treatment Areas